



- 1 -

07/809379
08/31/935 KA

**DERIVATIZED DTPA COMPLEXES, PHARMACEUTICAL AGENTS
CONTAINING THESE COMPOUNDS, THEIR USE, AND
PROCESSES FOR THEIR PRODUCTION**

Cross-Reference to Related Applications

5 ~~This application is a continuation of Application Serial~~
~~No. 07/809,830, filed December 20, 1991, which is a~~
~~continuation of Application Serial No. 07/780,840, filed~~
~~October 23, 1991, which is a continuation in part of~~
~~Application Serial No. 07/544,530, filed June 28, 1990, the~~
10 ~~disclosures of which are hereby incorporated by reference.~~

Background of the Invention

15 The invention relates to novel complexes and complex
salts, agents containing these compounds, their use in
diagnostics and therapy, as well as processes for
preparing these compounds and agents.

20 Metallic complexes have been scrutinized as early as
at the beginning of the fifties as contrast media for
radiology. The compounds then employed were, however, of
such toxicity that utilization on human patients could
not be considered. It was, therefore, entirely
surprising to find that certain complex salts exhibit
adequate compatibility for considering routine
administration to human patients for diagnostic purposes.
25 The first representative of this class of compounds was
the dimeglumine salt of Gd DTPA [gadolinium(III) complex
of diethylenetriaminepentaacetic acid] described in the
European Patent Application, Publication No. 71564, which
proved itself very well in the form of a contrast medium
for nuclear spin tomography. This compound has been
30 registered, under the name of "Magnevist", worldwide as
the first NMR diagnostic agent.

3 X

a Contrast media exhibiting (an at least ~~only~~ partial extrarenal excretion would be desirable, in particular for patients with limited kidney function.

Consequently, there is a need for NMR contrast media
5 exhibiting various pharmacokinetic behaviors.

Summary of the Invention

The invention makes such compounds and media available, and also provides a process for their production.

10 The compounds according to this invention display renal elimination as well as excretion with feces.

Surprisingly, elimination via the gallbladder, however, is not the only extrarenal path of elimination: in NMR studies on rats, upon intravenous administration
15 of the compounds of this invention, a contrast enhancement of the gastrointestinal tract has also been unexpectedly observed. The kidneys, as well as implanted tumors, are likewise visualized with improved contrast.

The elimination (secretion) by way of the stomach
20 has the advantage that demarcation of abdominal structures (e.g., the pancreas) from the gastrointestinal tract is made possible, with a simultaneous contrast enhancement of pathological processes (tumors, inflammations). Imaging of the renal system, of the
25 liver and gallbladder, and the bile ducts can moreover likewise be achieved. Besides the improved visualization of ulcers and stomach carcinomas, it is also possible

to perform studies regarding gastric acid secretion with the aid of imaging procedures.

Accordingly, by making the compounds of this invention available, help can be extended to patients with renal insufficiency as well as patients suffering from gastrointestinal disorders (at least 10% of the population in the Western industrial countries). Most of these patients, as well as a large number of patients suspected of harboring such disease, must submit to diagnostic tests. At present, two methods suitable for this purpose are utilized above all: Endoscopy and X-ray diagnostics with the aid of barium contrast media.

These tests exhibit various drawbacks: they carry the risk of radiation stress, cause trauma, are connected with inconvenience, occasionally even with risk to the patient, and thus can evoke psychological stress. In most instances, these tests must be repeated; their performance is relatively complicated, require the patient's active cooperation (e.g., assumption of a specific bodily attitude) and frequently cannot be employed in case of frail and high-risk patients.


Provision of novel diagnostic methods for the identification and localization of gastrointestinal diseases, which methods do not exhibit these drawbacks, has thus likewise been attained by the complex compounds and agents according to this invention.

Their pharmacokinetics permits, even without specific measures, an improvement in the diagnosis of numerous diseases. The complexes for the most part are excreted again in unchanged form and rapidly so that, especially also in case of using relatively toxic metallic ions, no damaging effects are observed even at high dosage.

The practical use of the novel complexes is also facilitated by their favorable chemical stability.


5

The compounds of this invention are characterized by general Formula I



wherein

5 Z^1 and Z^2 in each case independently mean the residue



wherein

m and n mean the numbers 0 - 20,

k, l, q and r mean the numbers 0 and 1, and

10

R means a hydrogen atom, an optionally OR^1 -substituted C_1 - C_6 -alkyl residue, or a CH_2COOR^1 group with R^1 meaning a hydrogen atom, a C_1 - C_6 -alkyl residue, or a benzyl group,

15

X means a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21 - 29, 42, 44 or 57-83,

with the proviso that at least two of the substituents X stand for a metal ion equivalent; that one of the substituents Z^1 and Z^2 stands for a hydrogen atom and the other is not H; that --

20

6

if n and l each mean the number 0 -- k and r do not each simultaneously mean the number 1, that $-(O)_r-R$ is not $-OH$; and that Z^1 and Z^2 are not $-CH_2-C_6H_4-O-CH_2-COOCH_2C_6H_5$ or $-CH_2-C_6H_4-O-(CH_2)_5-COOCH_2C_6H_5$, as well as their salts with
5 inorganic and/or organic bases, amino acids or amino acid amides.

If the agent of this invention is intended for use in NMR diagnostics, then the central ion of the complex salt must be paramagnetic. These are, in particular, the divalent and trivalent ions of the
10 elements of atomic numbers 21-29, 42, 44 and 58-70. Suitable ions are, for example, the chromium(III), manganese(II), iron(II), cobalt(II), nickel(II), copper(II), praseodymium(III), neodymium(III), samarium(III) and ytterbium(III) ions. On account of
15 their very strong magnetic moment, the gadolinium(III), terbium(III), dysprosium(III), holmium(III), erbium(III) and iron(III) ions are especially preferred.

If the agent of this invention is meant for X-ray diagnostics, then the central ion must be derived
20 from an element of a higher atomic number in order to obtain adequate absorption of the X-rays. It has been found that suitable diagnostic media for this purpose are those containing a physiologically compatible complex salt with central ions of elements of atomic
25 numbers between 21-29, 42, 44, 57-83; these are, for example, the lanthanum(III) ion and the above-cited ions of the lanthanide series.

The numbers standing for m and n are preferably 0 to 5.


30 Suitable as the alkyl substituents R and R^1 are straight-chain or branched hydrocarbons of up to 6, preferably up to 4 carbon atoms which, in case of R, are optionally substituted by one or several, preferably 1-3, hydroxy or C_1-C_6- , preferably C_1-C_4- alkoxy groups.

Examples that can be cited for optionally substituted alkyl groups are the methyl, hydroxymethyl, ethyl, 2-hydroxyethyl, 2-hydroxy-1-(hydroxymethyl)ethyl, 1-(hydroxymethyl)ethyl, propyl, isopropyl, 2- and 3-hydroxypropyl, 2,3-dihydroxypropyl, n-, sec- and tert-butyl, 2-, 3- and 4-hydroxybutyl, 2- and 3-hydroxyisobutyl, pentyl, 2-, 3- and 4-hydroxy-2-methylbutyl, 2,3,4-trihydroxybutyl, 1,2,4-trihydroxybutyl, cyclopentyl, cyclohexyl, 2,3,4,5,6-pentahydroxyhexyl groups as well as -- in case of the hydroxyalkyl groups -- their C_1 - C_6 -, preferably C_1 - C_4 -alkyl derivatives, i.e., the corresponding C_{1-6} -alkoxy groups.

Preferred substituents Z^1 and Z^2 are the $-CH_2-C_6H_4-OCH_3$, $-CH_2-C_6H_5$, $-CH_2-C_6H_4-O-CH_2-C_6H_4-OCH_3$, $-CH_2-O-CH_2-C_6H_5$, $-CH_2-C_6H_4-O-CH_2-COOH$, $-CH_2-C_6H_4-OC_2H_5$, $-CH_2-C_6H_4-OC_4H_9$, $-CH_2-C_6H_4-O-CH_2-C_6H_5$ residues. Thus, m preferably is 1, and/or q preferably is 1, k and/or r preferably is 1, etc., and two phenyl rings are preferably separated by $-O-CH_2$, etc.

In case not all of the acidic hydrogen atoms are substituted by the central ion, it is possible to replace one, several, or all remaining hydrogen atom(s) by cations of inorganic and/or organic bases or amino acids. Suitable inorganic cations are, for example, the lithium ion, the potassium ion, the calcium ion, the magnesium ion and, in particular, the sodium ion. Suitable cations of organic bases are, inter alia, those of primary, secondary or tertiary amines, such as, for example, ethanolamine, diethanolamine, morpholine, glucamine, N,N-dimethylglucamine and, in particular, N-methylglucamine. Suitable cations of amino acids are, for example, those of lysine, of arginine, and or ornithine. Suitable cations of amino acid amides are lysine methyl amide, glycine ethyl amide and serine methylamide.

The production of the complex compounds of this invention in accordance with general Formula I takes place by converting, in a manner known per se, compounds of general Formula II



wherein

R^2 means an acid blocking group,

Z^3 and Z^4 each means a hydrogen atom or the residue

$-(CH_2)_m-(C_6H_4)_q-OH$, with the proviso that

10 one of the substituents Z^3 and Z^4 is a hydrogen atom and the other is the indicated residue,

and m and q are as in Formula I

into a compound with the residue indicated for Z^1 and Z^2 , splitting off the acid blocking groups R^2 , reacting

15 the thus-obtained complex-forming acids of general

Formula I where X is a hydrogen atom (Formula I') with at

least one metal oxide or metal salt of an element of

atomic numbers 21-29, 42, 44 or 57-83, and subsequently

-- if desired -- substituting any present acidic

20 hydrogen atoms by cations of inorganic and/or organic
bases, amino acids or amino acid amides.

9

Suitable acid blocking groups R^2 are lower alkyl, aryl and aralkyl groups, e.g. the methyl, ethyl, propyl, n-butyl, tert-butyl, phenyl, benzyl, diphenylmethyl, triphenylmethyl, bis(p-nitrophenyl)methyl groups, as well as trialkylsilyl groups.

Splitting off of the blocking groups R^2 takes place according to methods known to one skilled in the art [for example, E. Wünsch, "Methoden der Org. Chemie" [Methods of Organic Chemistry] (Houben-Weyl), vol. XV/1, 4th ed., 1974, pp. 315 et seq.], for instance by hydrolysis, hydrogenolysis or alkaline saponification of the esters with an alkali in aqueous-alcoholic solution at temperatures of 0-50° C. Organic or inorganic acids are used for splitting off the tert-butyl esters which are especially advantageous for the present reactions: The ester compound dissolved in a suitable anhydrous organic solvent, but preferably the pulverized dry material, is combined either with a hydrogen halide solution in glacial acetic acid, with trifluoroacetic acid, or also with boron trifluoride diethyl etherate in glacial acetic acid and split off at temperatures of -10° C to 60° C, preferably at room temperature.

The compounds of general Formula II, serving as educts for the production of the complex compounds of this invention, are known (DOS 3,710,730 and literature cited therein) or can be synthesized analogously to the preparation directions described therein. The entire disclosure of USSR 07/430,442 ^{now abandoned} (corresponding to the mentioned DOS), of October 2, 1989, is hereby incorporated by reference herein.

A series of literature methods known to a person skilled in the art is available for reacting the known aliphatic or aromatic hydroxy compounds to the corresponding arylalkyl or dialkyl ethers (for example, J. March, Advanced Organic Chemistry, 3rd ed., 1985, pp. 342 et seq.).

20K
9/24/97

10

For this purpose, the compounds of Formula II wherein R^2 stands for an alkali-stable acid blocking group are dissolved in a polar aprotic solvent, such as, for example, tetrahydrofuran, dimethoxyethane or dimethyl sulfoxide, and combined with a base, such as, for example, sodium hydride, sodium hydroxide or alkali or alkaline earth carbonates, at temperatures of between -30°C and the boiling point of the respective solvent, but preferably between 0°C and 60°C .

A compound of general Formula III is added to this mixture



wherein Y means a nucleofugal entity, such as, for example, Cl, Br, I, $CH_3-C_6H_4SO_3$ or CF_3SO_3 , and the remaining indices have the same meanings as in general Formula I.

The reaction periods are 30 minutes to 8 hours, depending on the steric hindrance of the residues participating in the reaction.

As an alternative to the aforescribed reaction conditions, it is possible to produce aryl-alkyl as well as dialkyl ethers in a very advantageous way by phase transfer catalysis (Starks and Liotta, Phase Transfer Catalysis, Academic Press, N.Y. 1978, pp. 128-138).

For this purpose, the reaction is performed in a two-phase mixture of an aqueous base, preferably 30% sodium hydroxide solution, and a water-immiscible organic aprotic solvent. Suitable phase transfer catalysts are the compounds known to a person skilled in the art, but preferably tetraalkylammonium or tetraalkylphosphonium salts.

11

If it is desired to synthesize compounds of general Formula I wherein k, n, l and r = 0 and R means a hydrogen atom, then it is possible to conduct the synthesis in analogy to the methods known from the literature, starting with the corresponding unsubstituted amino acid (e.g. phenylalanine).

However, if a series of analogous compounds is to be synthesized, then it is recommended to prepare the phenol derivatives described in DOS 3,710,730 and to reductively remove the phenol function in accordance with literature methods known to those skilled in the art. Above all, the reduction of aryl diethyl phosphates with titanium can be cited which can be performed in a very advantageous way also in the presence of ester groups [S.C. Welch et al., J. Org. Chem. 43 : 4797-99 (1978) and literature cited therein]. In this procedure, the corresponding aryl diethyl phosphate is first formed from the phenolic educt by reaction with phosphoric acid diethyl ester chloride in a 70-100% yield, preferably by the use of sodium hydride as the base in a polar aprotic solvent. Subsequently, the reduction is performed with freshly prepared titanium metal. Preferably, anhydrous titanium(III) chloride is reduced by magnesium or potassium in anhydrous tetrahydrofuran under an inert gas for preparing highly active titanium.

The above-described diethyl phosphate is added to such a mixture and heated under reflux for 2-24 hours, preferably 6-16 hours. After the reaction is terminated, the mixture is optionally worked up by chromatography. It is also possible to employ the palladium-catalyzed reduction of the corresponding aryl triflates according to S. Cacchi et al., Tetr. Lett. 27 : 5541-44 (1986).

The thus-obtained compounds of general Formula I' wherein X means a hydrogen atom represent complexing agents. They can be isolated and purified or can be converted, without isolation, into metal
5 complexes of general Formula I with at least two of the substituents X meaning a metal ion equivalent.

a 10 The metal complexes of this invention can be produced in a way disclosed in Patent DE 3,401,052, by dissolving or suspending the metal oxide or a metal salt (e.g., the nitrate, acetate, carbonate, chloride or sulfate) of the element of atomic numbers 21-29, 42,
44 or 58-70 in water and/or a lower alcohol (such as methanol, ethanol or isopropanol) and reacting with a solution or suspension of the equivalent amount of the
15 complex-forming acid of general Formula I' wherein X means a hydrogen atom, preferably at temperatures of between 40° and 100° C, and subsequently -- if desired -- substituting any present acidic hydrogen atoms of acid groups by cations of inorganic and/or organic bases,
20 amino acids or amino acid amides.

a 25 Neutralization is herein effected with the aid of inorganic bases (for example, hydroxides, carbonates or bicarbonates) of, for example, sodium, potassium, lithium, magnesium or calcium and/or with the aid of organic bases, such as, inter alia, primary,
secondary and tertiary amines, e.g., ethanolamine, morpholine, glucamine, N-methyl- and N,N-dimethyl-glucamine, as well as basic amino acids, such as, for example, lysine, arginine and ornithine.

a 30 In order to prepare the neutral complex compounds, it is possible, for example, to add to the acidic complex salts in an aqueous solution or suspension such an amount of the desired bases that

the neutral point is reached. The resultant solution can subsequently be evaporated to dryness under vacuum. It is frequently advantageous to precipitate the thus-formed neutral salts by adding water-miscible solvents, such as, for example, lower alcohols (methanol, ethanol, isopropanol, and others), lower ketones (acetone and others), polar ethers (tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and others), and to obtain in this way crystallized products which can be readily isolated and easily purified. It proved to be especially advantageous to add the desired base as early as during the complexing to the reaction mixture, thereby saving a process step.

If the acidic complex compounds contain several free acidic groups, then it is frequently expedient to prepare neutral mixed salts containing inorganic as well as organic cations as the counterions.

This can be done, for example, by reacting the complexing acid in an aqueous suspension or solution with the oxide or salt of the element yielding the central ion and with half the amount of an organic base needed for neutralization, isolating the thus-formed complex salt, purifying same if desired, and then combining same for complete neutralization with the required amount of inorganic base. The sequence of adding the bases can also be reversed.

The pharmaceuticals of this invention can be prepared in a likewise conventional way by suspending or dissolving the complex compounds according to the invention -- optionally adding the additives customary in galenic pharmacy -- in an aqueous medium and then optionally sterilizing the suspension or solution. Suitable additives are, for example, physiologically acceptable buffers (e.g. tromethamine), small additions

of complexing agents (such as, for example, diethylene-
triaminepentaacetic acid) or, if necessary, electro-
lytes (such as, for example, sodium chloride) or,
if necessary, antioxidants, e.g. ascorbic acid.

5 If, for enteral administration or other
purposes, suspensions or solutions of the agents of
this invention in water or a physiological saline solu-
tion are desirable, they are mixed with one or several
auxiliary agent(s) customary in galenic pharmacy
10 (for example methylcellulose, lactose, mannitol)
and/or tenside(s), e.g. lecithins, "Tween", "Myrj"
and/or flavoring substance(s) for taste improvement
(e.g. ethereal oils).

15 In principle, it is also possible to prepare
the pharmaceuticals of this invention even without
isolation of the complex salts. In any event, special
care must be directed toward effecting the chelate
formation so that the salts and salt solutions accord-
ing to this invention are practically devoid of toxic-
20 ally active metal ions that are not complexed.

 This can be ensured, for example, with the
aid of color indicators, such as xylenol orange, by
control titrations during the manufacturing process.
Consequently, the invention also relates to processes
25 for preparing the complex compounds and their salts.
The final safety feature resides in purification of
the isolated complex salt.

 The pharmaceutical agents of this invention can
be administered to mammals, including humans, in a dose of
30 1 $\mu\text{mol/kg}$ to 5 mmol/kg , preferably 10 μmol to 0.5 mmol/kg
of the complex salt according to the invention. For intra-
venous injection, aqueous formulations are utilized with a
concentration of 50 $\mu\text{mol/l}$ to 2 mol/l , preferably 100 mmol/l
to 1 mol/l . Rectal as well as oral administration is

15

preferably performed with solutions of a concentration of 0.1 mmol/l to 100 mmol/l. The volumes administered are between 5 ml and 2 l, depending on the diagnostic problem.

5 The agents according to this invention meet the variegated prerequisites for suitability as contrast media. Thus, they are excellently suited, upon enteral or parenteral administration, to improve the information content of the image obtained with the aid of the NMR
10 tomograph, by increasing the signal intensity. They show furthermore the high efficacy necessary for burdening the body with minimum amounts of foreign substances, and the good compatibility required for maintaining the non-invasive character of the tests.

15 The high water solubility and low osmolality of the agents according to this invention permits the production of highly concentrated solutions so that the volume load on the circulation is maintained within tolerable limits and dilution by body fluids is compensated. Furthermore, the agents of this invention
20 exhibit not only a high stability in vitro but also a surprisingly high stability in vivo so that release or exchange of the --actually toxic -- ions not covalently bound in the complexes takes place only extremely
25 gradually within the time wherein the novel contrast media are again entirely eliminated.

 The agents of this invention can also be utilized for radiation therapy. Thus, complexes of gadolinium are excellently suited due to the large
30 capture cross section for neutron capture therapy. If the agent of this invention is intended for use in the version of radiation therapy proposed by R.L. Mills et al. [Nature, 336 : 787 (1988)], then the central

16

ion must be derived from a Mössbauer isotope, such as, for example, ^{57}Fe or ^{151}Eu .

When administered, the agents of this invention can also be given together with a suitable carrier, such as, for example, serum or physiological saline solution and/or together with a protein, such as, for example, human serum albumin. The dosage herein is dependent on the type of cellular disorder and on the properties of the metal complex utilized.

10 In certain aspects, this invention can exclude compounds and compositions wherein Z^1 is phenyl and Z^2 is H and aspects wherein, when $-(O)_r-R$ is alkoxy, k, l, and q are simultaneously zero.

flk
4-24-97

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not
5 limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and unless otherwise indicated, all parts and percentages
10 are by weight.

The entire disclosures of all applications, patents and publications, if any, cited above and below, and of corresponding application Federal Republic of Germany
15 P 39 22 005.2, filed June 30, 1989, ^{now DE 3922005,} are hereby incorporated by reference.

LCK
4-24-97

18

Example 1

(a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-
4-(4-methoxybenzyl)undecanedioic Acid
Di-tert-butyl Diester

5 At 0° C, 1.56 g (2 millimoles) of 3,6,9-
triaz-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-
hydroxybenzyl)undecanedioic acid di-tert-butyl diester
(Example 9f of DOS 3,710,730) is combined in tetra-
hydrofuran with 66 mg (2.2 mmol) of 80% strength
10 sodium hydride. This mixture is combined with
0.31 g (2.2 mmol) of iodomethane and stirred for
30 minutes. Then the solution is combined with water,
tetrahydrofuran is removed by distillation, and the
aqueous emulsion is extracted with diethyl ether.
15 The organic phase is washed with water, dried over
Na₂SO₄, and concentrated.

Yield: 1.55 g (97.6%)

Calculated:	C	63.53	H	9.01	N	5.29
Found:	C	63.37	H	8.96	N	5.32

20 (b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-
(4-methoxybenzyl)undecanedioic Acid

1.27 g (1.6 mmol) of the tert-butyl ester
described in Example 1(a) is dissolved in 25 ml of
trifluoroacetic acid and stirred for one hour at room
25 temperature. The solution is then combined with
diethyl ether, the precipitate is suctioned off,
washed with ether and dried at 40° C under vacuum
over phosphorus pentoxide. The crude product is dis-
solved in water and combined under agitation with
30 active carbon. The mixture is filtered off from the
carbon and lyophilized three times to remove residual
trifluoroacetic acid.

Yield: 0.62 g (75.4%)

Calculated: C 51.46 H 6.09 N 8.18

Found: C 51.27 H 6.02 N 8.11

5 (c) Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris-
(carboxymethyl)-4-(4-methoxybenzyl)undecanedioic
Acid

513 mg (1 mmol) of the complexing acid
described in Example 1(b) is dissolved in about 30 ml
of water and combined at 80° C with 181 mg (0.5 mmol)
10 of Gd_2O_3 . After 30 minutes, the almost clear solution
is filtered and the filtrate freeze-dried.

Yield: 649 mg (97.2%) based on the anhydrous
material

Calculated: C 39.57 H 4.23 N 6.29 Gd 23.55

15 Found: C 39.47 H 4.29 N 6.21 Gd 23.19

Disodium Salt of the Gadolinium Complex

The complex (500 mg, 0.75 mmol) obtained as
described above is dissolved in 10 times the amount of
water and combined by means of a microburette with
20 1.5 ml of a 1N sodium hydroxide solution.

After freeze-drying, 533 mg of white crystals
is obtained.

T_1 relaxation (1/mmol·sec) is

25 in water 4.54 ± 0.13
in plasma 6.89 ± 0.17

Di-N-methyl-D-glucamine Salt of
the Gadolinium Complex

3.34 g (5 mmol) of the gadolinium complex is
combined in 40 ml of water in portions with 1.96 g
5 (10 mmol) of N-methyl-D-glucamine under agitation.
After the base has been completely dissolved, the
product is freeze-dried. There remains 5.55 g of a
colorless crystalline compound.

H₂O content (Karl Fischer determination):
10 4.73%

(d) Europium Complex of 3,6,9-Triaza-3,6,9-tris-
(carboxymethyl)-4-(4-methoxybenzyl)undecanedioic
Acid

5.13 g (10 mmol) of the complexing acid
15 described in Example 1(b) is dissolved in about 30 ml
of water and combined at 80° C with 1.76 g (5 mmol) of
Eu₂O₃. After 30 minutes, the almost clear solution is
filtered and the filtrate freeze-dried.

Yield: 6.62 g

20 Analysis (based on anhydrous substance)

Calculated:	C	39.89	H	4.26	N	6.34	Eu	22.94
Found:	C	39.71	H	4.38	N	6.17	Eu	22.58

Disodium Salt of the Europium Complex

The complex described above (497 mg, 0.75 mmol)
25 is dissolved in 10 times the quantity of water and
combined by means of a microburette with 1.5 ml of a 1N
sodium hydroxide solution. After freeze-drying, 540 mg
of white crystals is obtained.

Di-N-methyl-D-glucamine Salt of the
Europium Complex

3.31 g (5 mmol) of the europium complex
is mixed in 40 ml of water in portions with 1.96 g
5 (10 mmol) of N-methyl-D-glucamine under agitation.
After the base has been completely dissolved, the
mixture is freeze-dried. There remains 5.63 g of a
colorless, crystalline compound.

(e) Iron(III) Complex of 3,6,9-Triaza-3,6,9-tris-
10 (carboxymethyl)-4-(4-methoxybenzyl)undecanedioic
Acid

5.13 g (10 mmol) of the complexing acid dis-
closed in Example 1(b) is dissolved in about 30 ml of
water and combined at 80° C with 798 mg (5 mmol) of
15 Fe₂O₃. After 30 minutes, the almost clear solution is
filtered and the filtrate freeze-dried.

Yield: 5.66 g

Analysis (based on anhydrous substance):

Calculated:	C	46.66	H	4.98	N	7.42	Fe	9.86
20 Found:	C	46.71	H	5.03	N	7.38	Fe	9.81

Disodium Salt of the Iron(III) Complex

The complex obtained as described above
(425 mg, 0.75 mmol) is dissolved in 10 times the amount
of water and combined by means of a microburette with
25 1.5 ml of a 1N sodium hydroxide solution. After freeze-
drying, 460 mg of white crystals is obtained.

Di-N-methyl-D-glucamine Salt of the
Iron(III) Complex

2.83 g (5 mmol) of the iron(III) complex is
combined in 40 ml of water in portions with 1.96 g
5 (10 mmol) of N-methyl-D-glucamine under agitation.
After the base has been completely dissolved, the
solution is freeze-dried. There remains 4.83 g of a
colorless, crystalline compound.

Analogously, with bismuth oxide, Bi_2O_3 ,
10 the bismuth complex is obtained as the disodium salt
and, respectively, as the di-N-methyl-D-glucamine salt.

Example 2

(a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonyl-
methyl)-5-(4-methoxybenzyl)undecanedioic
15 Acid Di-tert-butyl Ester

In accordance with the directions given in
Example 1(a), 3.9 g (5 mmol) of 3,6,9-triaza-3,6,9-
tris(tert-butoxycarbonylmethyl)-5-(4-hydroxybenzyl)-
undecanedioic acid di-tert-butyl ester (Example 17d in
20 DOS 3,710,730) is reacted to 3.61 g (91% of theory) of
the title compound.

Calculated: C 63.53 H 9.01 N 5.29

Found: C 63.59 H 9.07 N 5.27

(b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-5-(4-methoxybenzyl)undecanedioic Acid

5 3.18 g (4 mmol) of the tert-butyl ester described in Example 2(a) is treated in accordance with the directions set forth in Example 1(b) with trifluoroacetic acid and worked up, thus obtaining 1.62 g (79% of theory) of a colorless lyophilized product.

10 Calculated: C 51.46 H 6.09 N 8.18 --
Found: C 51.34 H 6.14 N 8.11

(c) Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris-(carboxymethyl)-5-(4-methoxybenzyl)undecanedioic Acid

15 According to the directions in Example 1(c), 1.03 g (2 mmol) of the complex-forming acid described in Example 2(b) is complexed with Gd_2O_3 , yielding 1.32 g (99% of theory) of a colorless lyophilized product.

20 Calculated: C 39.57 H 4.23 N 6.29 Gd 23.55
Found: C 39.51 H 4.19 N 6.25 Gd 23.61

The T_1 relaxation (1/mmol·sec) is

in water 4.17 ± 0.14

in plasma 6.61 ± 0.12

Example 3

(a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-
4-[4-(4-methoxybenzyloxy)benzyl]undecanedioic
Acid Di-tert-butyl Ester

5 At 0° C, 1.56 g (2 mmol) of 3,6,9-triaza-3,6,9-
tris(tert-butoxycarbonylmethyl)-4-(4-hydroxybenzyl)-
undecanedioic acid di-tert-butyl ester (Example 9f of
DOS 3,710,730) is combined in tetrahydrofuran with
66 mg (2.2 mmol) of 80% strength sodium hydride.
10 To this mixture is added 0.3 ml (2.2 mmol) of 4-
methoxybenzyl chloride and the mixture is stirred
overnight. The solution is then combined with water,
tetrahydrofuran is removed by distillation, and the
aqueous emulsion is extracted with diethyl ether.
15 The organic phase is washed with water, dried over
Na₂SO₄, and concentrated. The resultant colorless oil
is chromatographed on silica gel (ether/hexane 1:1).
Yield: 1.17 g (65% of theory) of a
colorless oil.

20 Calculated: C 65.38 H 8.62 N 4.67
Found: C 65.29 H 8.65 N 4.59

(b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-[4-
(4-methoxybenzyloxy)benzyl]undecanedioic Acid

25 1.80 g (2 mmol) of the tert-butyl ester set
forth in Example 3(a) is treated analogously to the
directions given in Example 1(b) with trifluoroacetic
acid and reacted to 905 mg (73% of theory) of colorless,
flaky lyophilized product.

30 Calculated: C 56.21 H 6.02 N 6.78
Found: C 56.10 H 5.98 N 6.82

25

(c) Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris-
(carboxymethyl)-4-[4-(4-methoxybenzyloxy)benzyl]-
undecanedioic Acid

Analogously to the directions given for
5 Example 1(c), 620 mg (1 mmol) of the complexing acid
described in Example 3(b) is complexed and worked
up, yielding 758 mg (98% of theory).

Calculated:	C	45.01	H	4.43	N	5.43	Gd	20.32
Found:	C	44.93	H	4.49	N	5.37	Gd	20.18

10 The T_1 relaxation (l/mmol·sec) amounts to
in water 4.23 ± 0.16
in plasma 6.99 ± 0.13

Example 4

15 (a) Diethyl Phosphate of 3,6,9-Triaza-3,6,9-tris-
(tert-butoxycarbonylmethyl)-4-(4-hydroxybenzyl)-
undecanedioic Acid Di-tert-butyl Ester

11.2 g (14.36 mmol) of the phenol disclosed
in DOS 3,710,730 (Example 9f) is dissolved in 100 ml
of absolute tetrahydrofuran (THF). To this mixture is
20 added 380 mg (15.8 mmol) of sodium hydride (prepared
from 50% NaH in paraffin oil by washing three times
with 10 ml of THF). After 30 minutes at room tempera-
ture, 2.60 g (15.0 mmol) of phosphoric acid diethyl
ester chloride is added and the mixture stirred for
25 24 hours at room temperature.

The solution is diluted with 500 ml of
ether and washed three times with 300 ml of 10% sodium
hydroxide solution. After drying the organic phase over
magnesium sulfate, the product is concentrated under
30 vacuum and the residue purified by flash chromatography
(eluent: ether/hexane = 1:1).

Yield: 11.97 g (91% of theory) of a pale-yellow oil.

Calculated:	C	59.00	H	8.58	N	4.59	P	3.38
Found:	C	58.88	H	8.63	N	4.63	P	3.30

- 5 (b) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonyl-methyl)-4-benzylundecanedioic Acid Di-tert-butyl Ester

A mixture of 1.33 g (8.62 mmol) of anhydrous titanium(III) chloride and 1.02 g (26.09 mmol) of finely chopped potassium in 20 ml of tetrahydrofuran
10 is heated under reflux in an argon atmosphere for one hour.

Within 15 minutes, a solution of 11.5 g (12.55 mmol) of the compound described in Example 4(a) in 50 ml of tetrahydrofuran is added dropwise to this
15 mixture. Then the mixture is heated under reflux for 8 hours, cooled in an ice bath, 20 ml of methanol is gently added, then 100 ml of water is added, and the mixture is extracted three times with 200 ml of ether. The organic phases are dried over magnesium sulfate
20 and concentrated under vacuum. The residue is chromatographed on silica gel (eluent: hexane/ether = 2:1), thus obtaining 8.9 g (93% of theory) of the title compound as a colorless oil which crystallizes upon standing.

25	Calculated:	C	64.46	H	9.10	N	5.50
	Found:	C	64.54	H	9.15	N	5.41

(c) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-benzylundecanedioic Acid

5 Analogously to the directions set forth in Example 1(b), 7.64 g (10 mmol) of the tert-butyl ester described in Example 4(b) is reacted to 4.01 g (83% of theory) of the title compound.

Calculated: C 52.17 H 6.05 N 8.69
Found: C 52.23 H 5.99 N 8.73

10 (d) Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris-(carboxymethyl)-4-benzylundecanedioic Acid

2.42 g (5 mmol) of the complex-forming acid described in Example 4(c) is reacted analogously to the directions given in Example 1(c) to 3.14 g (98.5% of theory) of the title compound, obtaining
15 the gadolinium complex as a colorless, flaky lyophilized product.

Calculated: C 39.55 H 4.11 N 6.59 Gd 24.66
Found: C 39.47 H 4.19 N 6.52 Gd 24.88

20 The T_1 relaxation (1/mmol·sec) is
in water 4.54 ± 0.13
in plasma 6.89 ± 0.17

Ytterbium Complex of 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-benzylundecanedioic Acid

25 Analogously to the directions for preparing the gadolinium complex, the corresponding ytterbium complex is obtained by using Yb_2O_3 in place of Gd_2O_3 .

28

Example 5

(a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonyl-methyl)-4-benzyloxymethylundecanedioic Acid
Di-tert-butyl Ester

5 Within 30 minutes, 7.2 ml (60 mmol) of benzyl
bromide is added dropwise at room temperature to a
thoroughly stirred suspension of 14.1 g (20 mmol) of
4-hydroxymethyl-3,6,9-triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-
undecanedioic di-tert-butyl diester described in DOS
10 3,710,730 (Example 37d) and 0.3 g of tetrabutylammonium
hydrogen sulfate in 200 ml of dichloromethane/200 ml of
30% strength sodium hydroxide solution, and the mix-
ture is then agitated for 8 hours.

 400 ml of water is added to this suspension;
15 the organic phase is separated and the aqueous phase
extracted twice with respectively 150 ml of dichloro-
methane. After drying the combined organic phases
over magnesium sulfate, the product is chromatographed
on silica gel (ether/hexane = 1:1), thus obtaining
20 13.0 g (82% of theory) of the title compound as a
colorless oil.

Calculated: C 63.53 H 9.01 N 5.29
Found: C 63.42 H 9.07 N 5.21

25 (b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-
benzyloxymethylundecanedioic Acid

 Analogously to the directions given for Ex-
ample 1(b), 7.94 g (10 mmol) of the tert-butyl ester
set forth in Example 5(a) is reacted with trifluoro-
acetic acid, to 4.06 g (79% of theory) of the title
30 compound.

29

Calculated:	C	51.46	H	6.09	N	8.18
Found:	C	51.51	H	6.06	N	8.12

5 (c) Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris-
(carboxymethyl)-4-benzyloxymethylundecanedioic
Acid

10 In analogy to the directions in Example 1(c),
2.57 g (5 mmol) of the complexing acid described in
Example 5(b) is reacted to 3.30 g (98.9% of theory)
of the title compound, yielding a colorless, flaky
solid.

Calculated:	C	39.57	H	4.23	N	6.29	Gd	23.55
Found:	C	39.51	H	4.26	N	6.35	Gd	23.27

15 The T_1 relaxation (1/mmol·sec) is
in water 4.39 ± 0.12
in plasma 6.31 ± 0.15

Example 6

(a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonyl-
methyl)-4-(4-carboxymethoxybenzyl)undecanedioic
Acid Bis(tert-butyl) Ester

20 At 0° C, 23.40 g (30 mmol) of 3,6,9-triaza-
3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-hydroxy-
benzyl)undecanedioic acid di-tert-butyl ester (Ex-
ample 9f of DOS 3,710,730) is combined in tetrahydro-
25 furan with 2.7 g (90 mmol) of 80% strength sodium
hydride. To this mixture is dropped 6.25 g (45 mmol) of
bromoacetic acid in tetrahydrofuran, and the mixture
is stirred for one hour at 0° C and overnight at room
temperature.

30 The solution is then combined with water,
tetrahydrofuran is removed by distillation, and the

aqueous phase is extracted with ethyl acetate. The organic phase is dried over sodium sulfate and concentrated.

5 The residue is chromatographed on silica gel in an eluent mixture of dioxane/methanol/triethylamine (15:4:1); the combined fractions are concentrated and divided between ethyl acetate and 1N citric acid. The organic phase is then dried over sodium sulfate and concentrated, thus obtaining 21.8 g (87% of theory)
10 as a colorless oil.

Calculated: C 61.63 H 8.54 N 5.01
Found: C 61.62 H 8.62 N 4.95

(b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-carboxymethoxybenzyl)undecanedioic Acid

15 Analogously to the directions given for Example 1(b), 21.0 g (25 mmol) of the tert-butyl ester described in Example 6(a) is reacted to 11.0 g (78.9% of theory) of the title compound.

Calculated: C 49.55 H 5.60 N 7.54
20 Found: C 49.31 H 5.51 N 7.47

(c) Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris-(carboxymethyl)-4-(4-carboxymethoxybenzyl)-undecanedioic Acid

5.57 g (10 mmol) of the complex-forming acid
25 described in Example 6(b) is reacted analogously to the directions set forth in Example 1(c) to yield 7.01 g (98.5% of theory) of the title compound.

Calculated: C 38.81 H 3.96 N 5.90 Gd 22.09
Found: C 38.75 H 3.89 N 5.97 Gd 21.93

The T_1 relaxation (1/mmol·sec) is

in water 5.00 ± 0.01

in plasma 7.10 ± 0.08

Example 7

- 5 Preparation of a Solution of the Sodium Salt of the Gadolinium(III) Complex of 3,6,9-Triaza-3,6,9-tris-(carboxymethyl)-4-benzyloxymethylundecanedioic Acid

6.68 g (10 mmol) of the gadolinium complex
obtained according to Example 5(c) is dissolved in
10 70 ml of water pro injectione (p.i.) and combined
dropwise with 1N sodium hydroxide solution until a
pH of 7.2 has been reached. After adding 0.02 g of
tromethamine, the mixture is filled up to 100 ml with
water p.i.; the solution is dispensed into bottles and
15 heat-sterilized.

Example 8

- (a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonyl-
methyl)-4-(4-ethoxybenzyl)undecanedioic Acid
Di-tert-butyl Diester

20 At 0° C, 5.85 g (7.5 mmol) of 3,6,9-triaza-
3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-hydroxy-
benzyl)undecanedioic acid di-tert-butyl diester
(Example 9f of DOS 3,710,730) is combined in 100 ml
of tetrahydrofuran with 0.30 g (10 mmol) of 80%
25 strength sodium hydride. To this mixture is added
1.56 g (10 mmol) of iodoethane and the mixture is
stirred for 3 hours. Then the solution is combined
with water, tetrahydrofuran is distilled off, and the
aqueous emulsion is extracted with diethyl ether.
30 The crude product obtained after drying over sodium

sulfate and concentration of the solvent is chromatographed on silica gel (system: hexane/ether/triethylamine 70:30:5).

Yield: 4.0 g (66%)

5 Analysis (based on anhydrous material):

Calculated: C 63.91 H 9.11 N 5.20

Found: C 63.67 H 9.05 N 5.28

(b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid

10 3.64 g (4.5 mmol) of the tert-butyl ester disclosed in Example 8(a) is dissolved in 25 ml of trifluoroacetic acid, stirred for one hour at room temperature, and worked up analogously to Example 1(b).

Yield: 1.2 g (50.6%)

15 Analysis (based on anhydrous substance):

Calculated: C 52.36 H 6.13 N 7.97

Found: C 52.21 H 6.39 N 7.84

(c) Disodium Salt of the Gadolinium Complex of
3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid

20 528 mg (1 mmol) of the complex-forming acid described in the preceding example is dissolved in 40 ml of water and complexed at 80° C with 181 mg (0.5 mmol) of Gd_2O_3 . Then the mixture is neutralized
25 with 2 ml of 1N NaOH, stirred with activated carbon, filtered, and the filtrate is freeze-dried.

Yield: 700 mg (96.5%)

Analysis (based on anhydrous material):

Calculated: C 38.06 H 3.89 Gd 21.67 N 5.79 Na 6.34
Found: C 37.91 H 3.99 Gd 21.30 N 5.69 Na 6.57

The T_1 relaxation (1/mmol·sec) is

5 in water 5.33 ± 0.13
in plasma 8.69 ± 0.53

Analogously, the corresponding europium complex is obtained with europium oxide, Eu_2O_3 .

10 Calculated: C 38.34 H 3.92 Eu 21.09 N 5.83 Na 6.38
Found: C 38.20 H 4.01 Eu 20.87 N 5.79 Na 6.49

With iron oxide, Fe_2O_3 , the corresponding iron complex is obtained analogously:

Calculated: C 44.25 H 4.52 Fe 8.95 N 6.73 Na 7.37
Found: C 44.17 H 4.59 Fe 8.52 N 6.81 Na 7.49

15 Example 9

(a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-butoxybenzyl)undecanedioic Acid
Di-tert-butyl Diester

20 Analogously to Example 8(a), 5.85 g
(7.5 mmol) of 3,6,9-triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-hydroxybenzyl)undecanedioic acid di-tert-butyl diester (Example 9f of DOS 3,710,730) is
reacted with 1.84 g (10 mmol) of 1-iodobutane and
worked up as described therein.

25 " Yield: 4.1 g (65.4%)

Analysis (based on anhydrous compound):

Calculated: C 64.64 H 9.28 N 5.03
Found: C 64.82 H 9.37 N 4.96

5 (b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-butoxybenzyl)undecanedioic Acid

3.34 g (4 mmol) of the tert-butyl ester described in Example 9(a) is dissolved in 20 ml of trifluoroacetic acid, stirred for one hour at room temperature, and worked up analogously to Example 1(b).
10 Yield: 1.36 g (61.0%)

Analysis (based on anhydrous material):

Calculated: C 54.04 H 6.71 N 7.57
Found: C 53.88 H 6.63 N 7.41

15 (c) Disodium Salt of the Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-butoxybenzyl)undecanedioic Acid

556 mg (1 mmol) of the complexing acid described in the preceding example is combined with 40 ml of water and complexed at 80° C with 181 mg (0.5 mmol) of Gd_2O_3 . The mixture is then neutralized with 2 ml of 1N NaOH, stirred with activated carbon, filtered, and the filtrate freeze-dried.
20

Yield: 711 mg (94.3%)

Analysis (based on anhydrous material):

25 Calculated: C 39.83 H 4.28 Gd 20.86 N 5.58 Na 6.10
Found: C 39.61 H 4.35 Gd 20.51 N 5.49 Na 6.17

35

The T_1 relaxation (1/mmol·sec) is

in water 5.80 ± 0.26

in plasma 14.20 ± 0.98

5 Analogously, with the use of europium oxide, Eu_2O_3 , the corresponding europium complex is obtained:

Calculated: C 40.11 H 4.31 Eu 20.30 N 5.61 Na 6.14

Found: C 39.97 H 4.39 Eu 20.02 N 5.72 Na 6.25

With iron oxide, Fe_2O_3 , the corresponding iron complex is analogously obtained:

10 Calculated: C 46.03 H 4.94 Fe 8.56 N 6.44 Na 7.05

Found: C 45.88 H 5.03 Fe 8.30 N 6.50 Na 7.11

Example 10

15 (a) 3,6,9-Triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-benzyloxybenzyl)undecanedioic Acid Di-tert-butyl Diester

Analogously to Example 8(a), 5.85 g (7.5 mmol) of 3,6,9-triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-hydroxybenzyl)undecanedioic acid di-tert-butyl diester (Example 9f of DOS
20 3,710,730) is reacted with 1.71 g (10 mmol) of benzyl bromide and worked up as described therein.

Yield: 4.9 g (75.1%)

Analysis (based on anhydrous substance):

Calculated: C 66.25 H 8.69 N 4.83

25 Found: C 66.14 H 8.77 N 4.83

(b) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-benzyloxybenzyl)undecanedioic Acid

3.48 g (4 mmol) of the tert-butyl ester disclosed in Example 10(a) is dissolved in 20 ml of trifluoroacetic acid, stirred for one hour at room temperature, and worked up analogously to Example 1(b).

Yield: 1.33 g (56.5%)

Analysis (based on anhydrous material):

Calculated:	C	57.04	H	5.98	N	7.13
10 Found:	C	56.89	H	6.03	N	7.21

(c) Disodium Salt of the Gadolinium Complex of 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-benzyloxybenzyl)undecanedioic Acid

590 mg (1 mmol) of the complexing acid described in the preceding example is combined with 40 ml of water and 1 ml of 1N NaOH and complexed at 80° C with 181 mg (0.5 mmol) of Gd₂O₃. Then the mixture is neutralized furthermore with 1 ml of 1N NaOH, stirred with active carbon, filtered, and the filtrate freeze-dried.

Yield: 703 mg (89.2%)

Analysis (based on anhydrous material):

Calculated:	C	42.69	H	3.84	Gd	19.96	N	5.33	Na	5.84
Found:	C	42.63	H	3.91	Gd	19.57	N	5.26	Na	5.99

The T₁ relaxation (1/mmol·sec) is
in water 5.81 ± 0.11
in plasma 16.35 ± 1.01

The corresponding europium complex is obtained analogously with europium oxide, Eu_2O_3 :

Calculated: C 42.98 H 3.86 Eu 19.42 N 5.37 Na 5.88

Found: C 43.10 H 3.91 Eu 19.13 N 5.27 Na 5.99

5 With iron oxide, Fe_2O_3 , the corresponding iron complex is obtained analogously:

Calculated: C 48.99 H 4.41 Fe 8.14 N 6.12 Na 6.70

Found: C 48.73 H 4.57 Fe 8.29 N 6.03 Na 6.85

Yck
5-14-97

38

-- Example 11

a) 4-Nitro-N-benzyloxycarbonyl-DL-phenylglycine-(2-aminoethyl)-amide-hydrochloride

588.5 g (3 mol) of 4-nitro-DL-phenylglycine, produced according to J. Biochem. (Tokyo) 88(6), 1773, is suspended in 2.5 liters of ethanol. 713.8 g (6 mol) of thionyl chloride is instilled under ice cooling within 90 minutes, refluxed for two hours, and the resulting solution is evaporated to dryness in a vacuum. The residue is dissolved in 5 liters of water, mixed with 5 liters of diethyl ether and brought to pH 8.5 with 1.5 liters of a 1.5 M-sodium carbonate solution. Then, 511.8 g (3 mol) of chloroformic acid benzyl ester and 1.8 liters of 1.5 M-sodium carbonate solution are instilled simultaneously with intensive stirring, so that the pH of the mixture is between 8.2 and 8.6. It is allowed to stir for two hours at room temperature, the organic phase is separated, it is washed neutral with water, dried on sodium sulfate and the filtered solution is evaporated to dryness. The residue is dissolved in 2 liters of methanol, and the solution is instilled slowly in 3.5 liters of ethylenediamine with intensive stirring. It is allowed to stir for 24 hours, evaporated to dryness in a vacuum, the residue is dissolved in 2 liters of hot methanol and the solution is mixed by instillation under cooling with conc. hydrochloric acid until permanent turbidity. It is allowed to crystallize in the ice bath for 24 hours, the precipitate is suctioned off, it is washed

with a little ice-cold methanol and it is dried in a vacuum at 40°C.

1022.3 g (90% of theory) of the title compound is obtained as a yellow powder with an uncharacteristic decomposition point.

Analysis:

C	52.88	H	5.18	N	13.70	(calculated)
	52.61		5.24		13.77	(found)

b) 1,5-Diamino-3-aza-1-(4-nitrophenyl)-pentane

255.5 g (0.625 mol) of the compound obtained under a) is suspended in 650 ml of a solution of hydrobromic acid in glacial acetic acid. It is allowed to stir for 30 minutes at room temperature and the solution is mixed with diethyl ether until permanent turbidity. After stirring overnight, the precipitated hydrobromide is suctioned off, dried and dissolved in 2 liters of water. After treatment with 1.25 liters of AMBERLITE IRA 410 ion exchange material, the filtered solution is evaporated to dryness and dehydrated by codistillation with toluene. The residue is dissolved in 500 ml of tetrahydrofuran and again concentrated by evaporation. Then, 4.5 liters of a one-molar diborane-tetrahydrofuran complex solution in tetrahydrofuran (ALDRICH) is added and refluxed for 72 hours. After cooling off the solution, 500 ml of methanol is carefully instilled and saturated under ice cooling with hydrochloric acid. It is allowed to stir for four more hours, the precipitate is suctioned off and dried in a vacuum after washing with tetrahydrofuran at room temperature.

170.9 g of the title compound is obtained as trihydrochloride of equivalent weight 113.4 (calculated: 111.2).

c) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-nitrophenyl)-undecanedioic acid

58.4 g (175 mmol) of the compound obtained under b) is dissolved in 630 ml of water and 420 ml of a 10 molar potassium hydroxide solution, mixed with 1.1 liters of tetrahydrofuran and, after the addition of 165.4 g (1.75 mol) of chloroacetic acid, stirred for 72 hours at 50°C. It is cooled off to room temperature, the aqueous phase is separated, neutralized with conc. hydrochloric acid, and the solution is evaporated to dryness in a vacuum. The residue is dehydrated by codistillation with toluene, 2 liters of ethanol is added and 312.3 g of thionyl chloride is instilled under ice cooling. It is refluxed for five hours, evaporated to dryness in a vacuum and the residue is mixed with 2 liters of ethyl acetate and 4 liters of a one-molar sodium bicarbonate solution. It is allowed to stir for two hours, the organic phase is separated, it is washed with water, dried on sodium sulfate, filtered and evaporated to dryness in a vacuum. The remaining yellow oil is the pentaethyl ester of the title compound. For saponification, 150 ml of tetrahydrofuran and 150 ml (750 mmol) of 5n sodium hydroxide solution are added and allowed to stir for four hours at room temperature. The aqueous phase is separated, filtered several times on activated carbon and acidified with 50% by volume of sulfuric acid. It is allowed to stir for 24 hours in an ice bath, the precipitate is suctioned

off, it is washed with ice water and dried in a vacuum at 50°C. 55.8 g (62% of theory) of the title compound is obtained as a white powder with a decomposition point above 250°C.

Analysis:

C	46.69	H	5.09	N	10.89	(calculated)
	46.48		5.20		11.01	(found)

d) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(hydroxyphenyl)-undecanedioic acid

51.4 g (0.1 mol) of the compound obtained under c) is suspended in 500 ml of water and brought into solution by adding conc. sodium hydroxide solution. The solution is mixed in an autoclave with 5 g of palladium-carbon catalyst (10% Pd) and saturated with hydrogen gas. After completion of the hydrogenation, it is suctioned off from the catalyst, the solution is filtered on activated carbon and mixed with 15 ml of glacial acetic acid. Then, a solution of 11 g (150 mmol) of sodium nitrite in 50 ml of water and 50 ml of glacial acetic acid is simultaneously instilled in the ice bath with stirring, so that an inner temperature of 5°C is not exceeded. It is allowed to stir for two hours at 5°C, then for two more hours at room temperature, 50 ml of nitric acid (1:3) is added by instillation and heated for three hours to 50°C. After cooling off and stirring in the ice bath overnight, the precipitate is suctioned off, washed with water and recrystallized from 90% ethanol. 29.1 g (60% of theory) of the title compound is obtained as a white powder with a decomposition point above 250°C.

Analysis:

C 49.48 H 5.61 N 8.66

49.52 5.80 8.62

e) 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxyphenyl)-undecanedioic acid

4.85 g (10 mmol) of the compound obtained under d) is dissolved in 20 ml of dimethyl formamide. After cooling off in the ice bath, 300 mg (10 mmol) of 80% sodium hydride and then 1.56 g (10 mmol) of iodine ethane are carefully added and allowed to stir at room temperature overnight. It is heated for two hours to 40°C, 5 ml of water is carefully instilled and the solution is evaporated to dryness in a vacuum. The residue is stirred up with 100 ml of diethyl ether overnight, suctioned off and suspended in 20 ml of 2n hydrochloric acid. It is allowed to stir for one hour, again suctioned off, washed with water and dried in a vacuum at 40°C. [Several words illegible] title compound is obtained as a white powder with an uncharacteristic decomposition point.

Analysis:

C 51.46 H 6.08 N 8.18

51.33 6.17 8.13


f) Disodium salt of the gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxyphenyl)-undecanedioic acid

5.0 g of the compound obtained under e) is reacted in 30 ml of water with 1812 mg (5 mmol) of gadolinium oxide at 80°C within one hour. The solution is ultrafiltered and freeze-dried. The title compound is obtained in quantitative yield with a gadolinium content of 22.1% (relative to the anhydrous substance).

Melting point: greater than 300°C.

Example 12: Analogously, as described in example 11, starting from 2-amino-4-(4-nitrophenyl)-butyric acid, the complexes, according to the invention, of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxyphenylethyl)-undecanedioic acid are obtained.

Melting point: greater than 300°C. --



PC
5-14-97

Examples for in vivo NMR Diagnostics

Example 1

Images were obtained at various times after administration of the disodium salt of the gadolinium complex of Example 1(c) to rats with the aid of an NMR tomograph by General Electric, specifically developed for animal experimental research.

Spin echo scans were made with the NMR tomograph (CSI 2 T) at 2 tesla (TR time of 400 ms and TE time of 20 ms). The layer thickness of this T_1 -weighted imaging sequence was 3 mm; the image matrix was 128 x 128.

The contrast medium was administered intravenously into a caudal vein of a male hairless rat (Lew/Mol) weighing 190 g, in a dose of 0.06 mmol/kg. The animal had a Brown Pearce tumor in the thigh and was anesthetized for the study by means of an intramuscular administration of "Ketavet"/"Rompun".

Various dark structures are visible in the abdomen in the coronary blank scan (baseline, No. 1). No differentiation was possible between intestinal lumen and stomach.

One minute after administration (No. 2), the first enhancement is already apparent in the urinary bladder. A strong increase in contrast is visible in the stomach 45 minutes after injection (No. 3). A good visualization of the tumor (at the level of the reference tube), of the urinary bladder, and of the stomach can be observed 60 minutes after injection (No. 4). Moreover, contrasting of the intestine can likewise be observed. This makes it possible to distinguish among intestinal loops, fat, as well as lymphatic nodes (lymphomas). Contrasting of the

45

M renal pelvis is also striking; this image can be even more improved 65 minutes after injection in a somewhat different layer (No. 5). ~~In Figure 6,~~ 180 minutes after injection, the contrast enhancement is likewise clearly recognizable in an axial scan in the zone of the liver. This makes it possible to differentiate among the stomach, the liver, the duodenum, and the pancreas.

Lok
514-97

Example 2

10 The test animals were female rats of the strain Lew/Mol weighing 160-180 g. Prior to imaging, the animals were anesthetized ("Rompun" + "Ketavet") and provided with a catheter in the caudal vein to administer the contrast medium. Imaging took place
15 in an MRI experimental device by General Electric (field strength 2 tesla). First of all, the images (7, 9, 11) were made without contrast medium with a T_1 -weighted spin echo sequence (TR = 400 msec, TE = 20 msec, axial section plane, layer thickness 3 mm).
20 The liver appears in each case with the normal signal intensity; the stomach is darker in tendency than the liver. In case of animal 1, the stomach exhibits, in part, a rather high signal intensity. This is due to feed residues, the feed containing manganese in
25 relatively high concentrations (at the time of the test, the animals had been fasting for 6 hours). Animal 3 had been implanted with an osteogenic sarcoma three weeks previously; this sarcoma was of equal contrast in the blank image and could not be defined.
30 The administration of contrast medium took place via the venous catheter with a dose of 0.1 mmol Gd/kg (concentration of the solutions 0.05 mmol Gd/ml in 0.9% NaCl) for all 3 compounds.

46

M
N
M
A marked enhancement of the liver can be found
for all 3 compounds after 90 minutes [~~Figure 8,~~
Example 8(c)] and, respectively, after 60 minutes have
elapsed upon administration [~~Figure 10,~~ Example 9(c);
5 Figure 12, Example 10(c)]; this is due to uptake by
the hepatocytes and cannot be observed at this point in
time after administration with the contrast medium
for NMR tomography, "Magnevist", heretofore the sole
contrast medium available on the market. In case of
10 animal 3 [~~Figure 12,~~ Example 10(c)], the tumor is now
additionally clearly visible, which has not absorbed
the contrast medium at all, or only to a lesser propor-
tion.

15 Furthermore, all compounds -- most strongly in
case of Example 10(c), least in case of Example 8(c) --
show great enhancement of the stomach. This offers
additional diagnostic possibilities in view of an improved
distinction of liver and stomach.

YCK
5-14-97

YCK
5-14-97

YCK
5-14-97

YCK
5/7/97

47

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

5

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and

10

conditions.